No annual revenue total was found in Lexeo Therapeutics, Inc.'s SEC filings.
Lexeo Therapeutics, Inc. (LXEO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$99.0 million. As of Jun 30, 2026 it held $234.2 million in cash and investments and $6.8 million in total debt.
Revenue
—
Net income
$-99.96M
-1.7% vs prior year
Operating cash flow (TTM)
$-88.37M
+7.0% vs year-ago TTM
Free cash flow (TTM)
$-88.70M
+6.9% vs year-ago TTM
EPS
$-1.86
+39.8% vs prior year
Dividend per share
None
Shares outstanding
74.09M
+123.2% vs prior year
Net cash
$227.36M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LXEO (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1907108
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Operating income | -$109.3M | -$105.8M | -$68.5M |
| Net income | -$100.0M | -$98.3M | -$66.4M |
| Diluted EPS | -$1.86 | -$3.09 | -$12.40 |
| Operating cash flow | -$98.6M | -$81.2M | -$59.5M |
| Free cash flow | -$99.0M | -$81.6M | -$59.6M |
| Total assets | $268.7M | $146.9M | $139.8M |
| Total liabilities | $22.0M | $30.1M | $26.3M |
| Stockholders' equity | $246.7M | $116.8M | $113.5M |
| Cash and investments | $246.6M | $128.5M | $121.5M |
| Total debt | $7.9M | $9.9M | $11.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Acquisition or sale of assets, Unregistered share sale
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 22, 2026 | Sep 16, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 15, 2026 |
All 360 Lexeo Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.